Astrana Health Third Quarter 2026 Earnings Call - VITRIA TECHNOLOGY INC

Explicit Guidance:

• 2027 EBITDA Growth: Management expects to deliver "at least mid-teens annual adjusted EBITDA growth" for the full year 2027.
• 2027 G&A Ratio: Full-year 2026 G&A is expected to remain around 6.2% of revenue; medium-term outlook anticipates "meaningful opportunity for further operating leverage" as AI capabilities mature.
• 2027 Medicaid Membership: Anticipates a "10% to 15% decline in Medicaid membership in 2027" due to policy changes (transition to fee-for-service, work requirements, eligibility redeterminations).
• 2027 Medical Cost Trends: Expects "modest" improvement in weighted average Star ratings for 2027, with margins remaining "stable into 2027" regarding Medicare Advantage rate exclusions.
• 2028 Outlook: Expects Medicare Advantage Star ratings to remain "relatively stable in 2028."
• Capitation Revenue Mix: Targets approximately 82% of capitation revenue to be generated under full-risk arrangements by the end of 2026 (up from 76% in 2025).

Business-Segment Outlook:

• Medicare Advantage (MA): Membership grew organically at a "high single-digit rate year-over-year" in Q3 2026; expects continued growth driven by "new Medicare Advantage partnerships effective January 1, 2027."
• Medicaid: Expects attrition in the "middle to high end of the 10-15% range" for 2026, with full-year 2027 outlook showing a 10-15% decline.
• Exchange Business: Membership attrition in 2026 was "more favorable" than the original assumption of 30-40%; business remains approximately 3% of revenue.
• Commercial: Membership remains "stable."
• Full-Risk Conversions: Approximately 46% of Care Partners members are now in full-risk arrangements (up from 34% YoY); Texas cohort (7,000 members moved to Global Risk, 3,000 to professional risk) is performing "ahead of plan" with medical cost trends running favorably.
• Provider Expansion: Completed tuck-in acquisition of an independent physician association in Georgia (Oct 1); added two new AI platform clients (CT primary care group, CA hospital) expected to be onboarded by "early 2027."

Market and Competitive Outlook:

• Industry Differentiation: Contrasts performance with competitors reducing Medicare Advantage footprints, highlighting Astrona's ability to grow organically while maintaining profitability.
• Operational Efficiency: Claims administration processes reduced from "hours to minutes" via AI agents; referral management and claims workflows reduced handling times by >50%.
• Platform Leverage: Expecting to reduce upfront investment for new market entry and accelerate path to profitability for new populations through the "flywheel" of data, AI, and clinical feedback loops.
• Payer Mix: Moving toward a diversified payer model to mitigate exposure to any single contract; currently engaged with "more than a dozen health plans."

Macro / Industry Outlook:

• Medicaid Policy: Anticipating structural headwinds in 2027 including "work requirements, more frequent eligibility redeterminations, and changes to asset limits."
• Medicare Rate Setting: Believes impact from "exclusion of certain diagnosis sources" in the 2027 final rate notice will be "immaterial."
• Medical Cost Pressures: Commercial medical cost trends remain "slightly above expectations" primarily due to "clinician-administered drug costs"; Medicaid trends are "highest," while Medicare Advantage and Original Medicare perform favorably.

Strategic Initiatives:

• AI Product Launch (Atlas): Launched "Atlas," the next-generation provider-facing platform, to prioritize high-risk patients and identify care gaps in real-time.
• Care Management Technology: Proprietary "Pathways" platform currently reaching nearly 65% of eligible members via annual wellness visits; expanding disease management programs for congestive heart failure, COPD, and chronic kidney disease.
• Acquisition Integration: Consolidating legacy Prospect payer arrangements into enterprise contracts; California growth operations now unified under a single team. Viewed as "part of our core business" rather than a separate integration initiative.
• Deleveraging: Net leverage at ~2.2x; repaid $116M debt in the first nine months of 2026; remains on track for full-year free cash flow guidance.

Risks and Headwinds to Outlook:

• Regulatory Changes: Medicaid policy shifts (work requirements, eligibility redeterminations) pose a risk to membership counts in 2027.
• Drug Costs: Clinician-administered drug costs are a specific driver of commercial medical trend pressures.
• Membership Attrition: Medicaid and Exchange attrition rates could impact top-line revenue despite offsetting MA growth.
• Execution Risk: Successful replication of the Texas operating model across additional markets is required to achieve projected profitability and risk management.

Management Tone on the Future:

• Confidence: "Confident in our ability to deliver at least mid-teens annual adjusted EBITDA growth"; views the Texas full-risk cohort as a "compelling example" and "important proof point."
• Reassurance: Repeatedly emphasizes that the business is "balanced," "responsible," and that performance is "in line with or ahead of our underwriting expectations."
• Strategic Clarity: Shifts tone from integration focus to "core business" management, signaling maturity in the acquired entity and the platform's ability to scale without significant new capital investment.

Miscellaneous:

• Tax Rate: No specific forward-looking tax rate guidance provided in the transcript.
• Dividends/Buybacks: No mention of future dividend programs or share buyback plans.
• Capex/Opex: No specific capital expenditure dollar amounts forecasted, though AI and technology platform development are highlighted as key investment areas driving operating leverage.